SAVE THE DATE
June 23-25, 2011 in Washington, DC. For more information visit curemeso.org/symposium. Stay tuned…
FDA Approves KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Patients with Unresectable or Metastatic Malignant Pleural Mesothelioma
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with
